{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444747494
| IUPAC_name = 2-(phenyl-(phenylmethyl)amino)ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
| image = Efonidipine structure.svg

<!--Clinical data-->
| tradename = Landel (ランデル)
| Drugs.com = {{drugs.com|international|efonidipine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 111011-63-3
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 119171
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2074922
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 40ZTP2T37Q
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 106463
| smiles            = O=P1(OCC(CO1)(C)C)C/4=C(/N\C(=C(\C(=O)OCCN(c2ccccc2)Cc3ccccc3)C\4c5cccc([N+]([O-])=O)c5)C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = NSVFSAJIGAJDMR-UHFFFAOYSA-N

<!--Chemical data-->
| chemical_formula =  
| C=34 | H=38 | N=3 | O=7 | P=1 
| molecular_weight = 631.65 g/mol
}}

'''Efonidipine''' ([[International Nonproprietary Name|INN]]) is a [[dihydropyridine]] [[calcium channel blocker]] marketed by Shionogi & Co. of [[Japan]]. It was launched in 1995, under the brand name '''Landel (ランデル)'''.  The drug blocks both [[T-type calcium channel|T-type]] and [[L-type calcium channels]].<ref>{{cite journal |vauthors=Tanaka H, Shigenobu K |title=Efonidipine hydrochloride: a dual blocker of L- and T-type Ca<sup>2+</sup> channels |journal=Cardiovasc. Drug Rev. |volume=20 |issue=1 |pages=81–92 |year=2002 |pmid=12070536 |doi= |url=}}</ref>

It has also been studied in atherosclerosis<ref name="pmid8188119">{{cite journal |vauthors=Toyoda K, Kitahara M, Yamashita T |title=[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=103 |issue=5 |pages=231–9 |date=May 1994 |pmid=8188119 |doi= |url=|display-authors=etal}}</ref> and acute renal failure.<ref name="pmid7896060">{{cite journal |vauthors=Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K |title=Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats |journal=Gen. Pharmacol. |volume=25 |issue=7 |pages=1451–8 |date=November 1994 |pmid=7896060 |doi= |url=}}</ref>

==References==
{{Reflist}}
* {{ja icon}} [http://www.shionogi.co.jp/med/kihon/img/pdf/LND.pdf Landel ランデル] (PDF) Shionogi & Co. April 2005.

{{Calcium channel blockers}}

[[Category:Aldosterone synthase inhibitors]]
[[Category:Calcium channel blockers]]
[[Category:Dihydropyridines]]
[[Category:Nitrobenzenes]]
[[Category:Carboxylate esters]]
[[Category:Phosphonate esters]]
[[Category:Anilines]]


{{Cardiovascular-drug-stub}}